Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.

In the study update in 2021, at a median follow-up of 35.5 months, Isa-Pd was found to significantly improve time-to-next treatment and PFS2 and there was a strong trend in OS benefit in the Isa-Pd arm (24.6 versus 17.7 months, HR = 0.76). 48 In 2020, the EMA and FDA approved the combination of isatuximab-Pd for MM patients who have received at least two previous treatments, including lenalidomide and a PI.

also in 5,725 other papers